Asthma affects 2 out of 10 people in Scotland and this chronic, variable, inflammatory disease is characterised by asthma attacks and symptoms including breathlessness and wheezing. [7] 'Mild' asthma ...
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Symbicort Turbuhaler contains two active ingredients in one inhaler: ...
Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol ...
AstraZeneca’s (AZ’s) Symbicort (budesonide/formoterol) Turbohaler 200/6 has been approved in the UK as the first and only combination reliever therapy for adults ...
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...
GlaxoSmithKline plc and Innoviva, Inc. announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback